• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

    8/20/24 3:06:01 PM ET
    $SCNI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SCNI alert in real time by email
    SC 13G/A 1 13g.htm AMENDMENT 3 TO SCHEDULE 13G

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Amendment No. 3 to
    SCHEDULE 13G



    INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    SCINAI IMMUNOTHERAPEUTCS LTD.
    (Name of Issuer)




    American Depositary Shares, each representing 4,000 Ordinary Shares, no par value
    (Title of Class of Securities)



    09073Q203
    (CUSIP Number)


    August 19, 2024
    (Date of Event Which Requires Filing of This Statement)


    Check the Appropriate box to designate the rule pursuant to which this schedule is filed:


            Rule 13d-1(b)
    X  Rule 13d-1(c)
          Rule 13d-1(d)




    1
    NAME OF REPORTING PERSONS
    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS
     
     
    DANIEL E. STONE
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
    (a)
    (b)
     
         
    3
    SEC USE ONLY
     
         
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
     
    5
    SOLE VOTING POWER
    NUMBER OF
     
    62,400
    SHARES
    6
    SHARED VOTING POWER
    BENEFICIALLY
     
    0
    OWNED BY
    7
    SOLE DISPOSITIVE POWER
    EACH
     
    62,400
    REPORTING
    8
    SHARED DISPOSITIVE POWER
    PERSON WITH
     
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    62,400
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* 
     
         
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
     
    7.4%
    12
    TYPE OF REPORTING PERSON*
     
    IN
    *SEE INSTRUCTIONS BEFORE FILLING OUT!


    Item 1 (a). Name of Issuer:

    Scinai Immunotherapeutics Ltd. (the “Issuer”)

    Item 1 (b). Address of Issuer’s Principal Executive Offices:

    Jerusalem Biopark, 2nd Floor
    Hadassah Ein Kerem Campus
    Jerusalem L3 00000

    Item 2 (a). Name of Person Filing:

    Daniel E. Stone

    Item 2 (b). Address of Principal Business Office or, if None, Residence:

    1200 Brickell Avenue, #1470
    Miami, FL 33131

    Item 2 (c). Citizenship:

    United States

    Item 2 (d). Title of Class of Securities:

    American Depositary Shares, each representing 4,000 Ordinary Shares, no par value

    Item 2  (e). CUSIP Number:

    09073Q203

    Item 3.
    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    (a)
    Broker or dealer registered under Section 15 of the Act;


    (b)
    Bank as defined in Section 3(a)(6) of the Act;


    (c)
    Insurance Company as defined in Section 3(a)(19) of the Act;


    (d)
    Investment Company registered under Section 8 of the Investment Company Act;


    (e)
    Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);


    (f)
    Employee benefit plan or endowment plan in accordance with Rule 13d-1(b)(1)(ii)(F);


    (g)
    Parent holding company or control person, in accordance with Rule 13d-1(b)(1)(ii)(G);


    (h)
    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

    (i)
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940:


    (j)
    Group, in accordance with Rule 13d-1(b)(1)(ii)(j).


    X
    If this statement is filed pursuant to Rule 13d-1(c), check this box.

    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities identified in Item 1.


    (a)
    Amount beneficially owned:

    62,400


    (b)
    Percent of class:

    7.4%


    (b)
    Number of shares as to which such person has:

    (i)
    Sole power to vote or to direct the vote:  62,400

           (ii)  Shared power to vote or to direct the vote:  0

         (iii)  Sole power to dispose or to direct the disposition of:  62,400

         (iv)  Shared power to dispose or to direct the disposition of:  0

    The reporting person filed a Schedule 13G with respect to the reporting person’s beneficial ownership of the securities on October 6, 2022, and amendments thereto on February 2, 2023, and January 24, 2024.  On March 12, 2024, the reporting person amended the Schedule 13G by filing a Schedule 13D.  This Amendment No. 3 to Schedule 13G, which updates the Schedule 13D, is being filed pursuant to Rule 13d-1(h).


    Instruction.  For computations regarding securities which represent a right to acquire an underlying security, see Rule 13d-3(d)(1).

    Item 5.
    Ownership of Five Percent or Less of a Class.

    If the statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ].


    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    N/A

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    N/A

    Item 8.
    Identification and Classification of Members of the Group.

    N/A

    Item 9.
    Notice of Dissolution of Group.

    N/A




    Item 10. Certification.


    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.



     
    August 20, 2024
     
    (Date)
       
       
     
    /s/ Daniel E. Stone
    Daniel E. Stone
     
    Get the next $SCNI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCNI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Scinai Announces Annual Financial Results for 2024

      JERUSALEM, May 7, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing novel and innovative biological drug candidates for the treatment of inflammation and immunology (I&I) related diseases and on providing CDMO services through its Scinai Bioservices business unit, today announced its annual financial results for the full year 2024. Full year 2024 Financial Summary Revenues for 2024, amounted to $658 thousands, compared to no revenues for 2023. The increase was due to the CDMO starting to generate revenues for the first time in 2024.R&D expenses for 2024, amounted to $5.6 million compared to $5.2

      5/7/25 4:01:00 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

      The webinar will explore PC111, a novel monoclonal antibody drug candidate with the potential to transform the treatment landscape for Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN). JERUSALEM, Israel, May 1, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and which provides CDMO services through its Scinai Bioservices unit, today announced that it will be hosting a webinar on Wednesday May 7th at, at 11:30 AM EST / 18:30 Israel time. The webinar will address the unmet needs in treating Pemphigus Vulgaris and Stevens-Johnson Syndrome/Toxic

      5/1/25 7:00:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

      Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

      3/27/25 9:25:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCNI
    Financials

    Live finance-specific insights

    See more
    • Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

      JERUSALEM, Nov. 22, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the nine months ended September 30, 2024 and provided a business update. Business Update & Recent Highlights Conversion of EIB Loan into Equity bringing shareholders' equity to $10 million On August 21, 2024, the Company announced that it had closed a Loan Restructuring Agreement, which included an amendment and restatement to the amended Finance Contract wi

      11/22/24 7:15:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

      JERUSALEM, Aug. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) (the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has signed a definitive Loan Restructuring Agreement (the "Restructuring Agreement") with its lender, the European Investment Bank (the "EIB").  The Restructuring Agreement also included an amendment and restatement to the Finance Contract (the "Finance Contract") between the parties. In connection with the transactions, an amount equal to approximately EUR 26.6 million (equal to approxim

      8/13/24 7:00:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

      JERUSALEM, July 8, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) (the "Company"), a biotechnology company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today announced that it has received an updated non-binding Letter of Intent ("LoI") from the European Investment Bank (the "EIB"). This updated LoI outlines specific indicative terms for converting the majority of the EIB's loan into equity in the form of preferred shares (the "Preferred Shares"), which are convertible into American Depositary Shares ("ADSs") representing 19.5% of the fully diluted capital of the Com

      7/8/24 8:14:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCNI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      11/14/24 4:28:57 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Scinai Immunotherapeutics Ltd.

      SC 13G/A - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      8/20/24 3:06:01 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by Scinai Immunotherapeutics Ltd.

      SC 13D - Scinai Immunotherapeutics Ltd. (0001611747) (Subject)

      3/12/24 4:17:13 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCNI
    SEC Filings

    See more
    • SEC Form 20-F filed by Scinai Immunotherapeutics Ltd.

      20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      5/7/25 7:42:20 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 20-F filed by Scinai Immunotherapeutics Ltd.

      NT 20-F - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      4/29/25 4:51:35 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by Scinai Immunotherapeutics Ltd.

      6-K - Scinai Immunotherapeutics Ltd. (0001611747) (Filer)

      3/27/25 12:16:39 PM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SCNI
    Leadership Updates

    Live Leadership Updates

    See more
    • Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

      Scinai files an application for Euro 12 million grant to fund next stage of development Pincell's monoclonal antibody, PC111, is in development for treating Pemphigus, Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)PC111 has already received an Orphan Drug Designation in Pemphigus by the European Medicine's AgencyAn application will be filed with the FDA for Orphan Drug and Breakthrough Designation in Pemphigus, as well as in SJS/TENScinai sees potential for accelerated approval given the severity of these diseases, PC111's innovative, non-immunosuppressive mode of action and the lack of effective alternative treatmentsJERUSALEM, March 27, 2025 /PRNewswire/ -- Scinai Imm

      3/27/25 9:25:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

      JERUSALEM, Dec. 5, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) ("Scinai" or the "Company"), a biopharmaceutical company specializing in the development of inflammation and immunology (I&I) biological products and offering CDMO services through its Scinai Bioservices unit, announced today the appointment of Prof. Michael Schön to its Scientific Advisory Board (SAB). Prof. Michael Schön is a distinguished Professor and Director of the Department of Dermatology, Venereology, and Allergology at the University Medical Center Göttingen. He also serves as Vice D

      12/5/24 8:25:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Scinai Welcomes Liat Halpert as Head of Business Development and Sales

      JERUSALEM, Feb. 13, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced the appointment of Liat Halpert as Head of Business Development and Sales. Halpert brings extensive pharmaceutical sales and marketing experience and joins Scinai following 14 years at Novartis, most recently having served as Marketing and Commercial Excellence Lead for cell and gene therapies for Central, Southern and Eastern Europe.     Scinai's broad pharmaceutical development experience, along with its end-to-e

      2/13/24 7:00:00 AM ET
      $SCNI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care